Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations (Q38910529)

7 September 2017

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations (English)

1 reference

7 September 2017

1 reference

1 reference

19

Mari Mino-Kenudson

0 references

Gad Getz

20

object named as

Gad Getz

1 reference

7 September 2017

10

Craig H Mermel

1 reference

7 September 2017

24

Levi A Garraway

1 reference

7 September 2017

21

Dora Dias-Santagata

1 reference

7 September 2017

23

Jeffrey A Engelman

1 reference

7 September 2017

22

A John Iafrate

1 reference

7 September 2017

25

Ryan B Corcoran

1 reference

7 September 2017

Leanne G Ahronian

1

1 reference

7 September 2017

Erin M Sennott

2

1 reference

7 September 2017

Eliezer M Van Allen

3

1 reference

7 September 2017

Nikhil Wagle

4

1 reference

7 September 2017

Eunice L Kwak

5

1 reference

7 September 2017

Jason E Faris

6

1 reference

7 September 2017

Jason T Godfrey

7

1 reference

7 September 2017

Koki Nishimura

8

1 reference

7 September 2017

Kerry D Lynch

9

1 reference

7 September 2017

Elizabeth L Lockerman

11

1 reference

7 September 2017

Anuj Kalsy

12

1 reference

7 September 2017

Joseph M Gurski

13

1 reference

7 September 2017

Samira Bahl

14

1 reference

7 September 2017

Kristin Anderka

15

1 reference

7 September 2017

Lisa M Green

16

1 reference

7 September 2017

Niall J Lennon

17

1 reference

7 September 2017

Tiffany G Huynh

18

1 reference

7 September 2017

11 February 2015

1 reference

7 September 2017

1 reference

7 September 2017

5

1 reference

7 September 2017

4

1 reference

7 September 2017

358-367

1 reference

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

7 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Beyond histology: translating tumor genotypes into clinically effective targeted therapies

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Targeting the RAF-MEK-ERK pathway in cancer therapy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Mutations of the BRAF gene in human cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

ERK inhibition overcomes acquired resistance to MEK inhibitors.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4390490

10.1158/2159-8290.CD-14-1518

22 August 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference

7 September 2017

1 reference